Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study [PDF]
Fang Zhao,1,* Yuqiu Li,1,* Yanjun Zhou,2 Enfeng Fu,1 Shanshan Zhu,1 Lulu Yu,1 Hangcheng Xu,1 Qing Li,1 Qiao Li,1 Pin Zhang,1 Jiani Wang,1 Hongnan Mo1 1Department of Medical Oncology, National Cancer Center/National Clinical Research ...
Zhao F +11 more
doaj +2 more sources
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice.
Stephen Ansell +2 more
exaly +2 more sources
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study. [PDF]
Background CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment‐related adverse events (TRAEs).
Julien K +16 more
europepmc +2 more sources
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis [PDF]
Background: Although clinical practice guidelines for the management of Immune Checkpoint Inhibitor (ICI)-related adverse events have recently been published, precise and nuanced toxicity data for combination ICI therapy are lacking. Therefore, herein we
R. Park +4 more
semanticscholar +4 more sources
Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events [PDF]
Treatment-related side effects are a major clinical problem in cancer treatment. They lead to reduced compliance to therapy as well as increased morbidity and mortality.
M. Pinter, W. Kwanten, R. Jain
semanticscholar +4 more sources
Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab [PDF]
Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC).
Naohiro Watanabe +10 more
doaj +2 more sources
As there are few validated tools to identify treatment‐related adverse events across cancer care settings, we sought to develop oncology‐specific “triggers” to flag potential adverse events among cancer patients using claims data.
Saul N. Weingart +7 more
semanticscholar +4 more sources
The role of age in treatment‐related adverse events in patients with head and neck cancer: A systematic review [PDF]
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed in advanced stage and therefore requires aggressive, multimodal treatment. Elderly patients are often excluded from standard therapy regimens purely based on age.
A. Coca-Pelaz +10 more
semanticscholar +6 more sources
Utilities for treatment-related adverse events in type 2 diabetes
The impact of Type 2 diabetes mellitus (T2DM) on health-related quality-of-life (HRQoL) is complex due to the burden of disease, lifelong treatment requirements, and comorbidities. This study aimed to capture UK societal utility values for health states associated with T2DM and treatment-related adverse events (AEs) to assess the burden of the disease ...
S. Shingler +6 more
semanticscholar +3 more sources
Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
BackgroundNeoadjuvant immunotherapy has preliminarily been effective in multiple resectable cancers. However, its safety is still largely unknown.MethodsA systematic literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library ...
Jiawei Xu +6 more
doaj +1 more source

